About: Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study
Creator	Tang, Shaohua Chen, Dong Cai, Jing Huang, Jianping Dai, Jianyi Su, Feifei Wu, Lianpeng Huang, Chongquan Li, Huanzheng Li, Shufei Lin, Xiaoling Lin, Xuan Mao, Tingting Shi, Jichan Sun, Baochang Xu, Chenyang Xu, Xueqin
source	MedRxiv
abstract	ABSTRACT OBJECTIVE To investigate the dynamics of viral RNA, IgM, and IgG and their relationships in patients with SARS-CoV-2 pneumonia over an 8-week period. DESIGN Retrospective, observational case series. SETTING Wenzhou Sixth Peoples Hospital PARTICIPANTS Thirty-three patients with laboratory confirmed SARS-CoV-2 pneumonia admitted to hospital. Data were collected from January 27 to April 10, 2020. MAIN OUTCOME MEASURES Throat swabs, sputum, stool, and blood samples were collected, and viral load was measured by reverse transcription PCR (RT-PCR). Specific IgM and IgG against spike protein (S), spike protein receptor binding domain (RBD), and nucleocapsid (N) were analyzed. RESULTS At the early stages of symptom onset, SARS-CoV-2 viral load is higher in throat swabs and sputum, but lower in stool. The median (IQR) time of undetectable viral RNA in throat swab, sputum, and stool was 18.5 (13.25-22) days, 22 (18.5-27.5) days, and 17 (11.5-32) days, respectively. In sputum, 17 patients (51.5%) had undetectable viral RNA within 22 days (short persistence), and 16 (48.5%) had persistent viral RNA more than 22 days (long persistence). Three patients (9.1%) had a detectable relapse of viral RNA in sputum within two weeks of their discharge from the hospital. One patient had persistent viral RNA for 59 days or longer. The median (IQR) seroconversion time of anti-S IgM, anti-RBD IgM, and anti-N IgM was 10.5 (7.75-15.5) days, 14 (9-24) days, and 10 (7-14) days, respectively. The median (IQR) seroconversion time of anti-S IgG, anti-RBD IgG, and anti-N IgG was 10 (7.25-16.5) days, 13 (9-17) days, and 10 (7-14) days, respectively. By week 8 after symptom onset, IgM were negative in many of the previously positive patients, and IgG levels remained less than 50% of the peak levels in more than 20% of the patients. In about 40% of the patients, anti-RBD IgG levels were 4-times higher in convalescence than in acute phase. SARS-CoV-2 RNA coexisted with antibodies for more than 50 days. Anti-RBD IgM and IgG levels, including anti-RBD IgM levels at presentation and peak time, were significantly higher in viral RNA short persistence patients than in long persistence patients. CONCLUSION This study adds important new information about the features of viral load and antibody dynamics of SARS-CoV-2. It is clear from these results that the viral RNA persists in sputum and stool specimens for a relatively long time in many patients. Anti-RBD may also serve as a potential protective antibody against SARS-CoV-2 infection, as viral persistence appears to be related to anti-RBD levels. Earlier treatment intervention also appears to be a factor in viral persistence.
has issue date	2020-04-27(xsd:dateTime)
bibo:doi	10.1101/2020.04.22.20071258
has license	medrxiv
sha1sum (hex)	cbfcc8ef7d0b19fda8e3d2001b34744c303af83b
schema:url	https://doi.org/10.1101/2020.04.22.20071258
resource representing a document's title	Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study
resource representing a document's body	covid:cbfcc8ef7d0b19fda8e3d2001b34744c303af83b#body_text
is schema:about of	named entity 'RNA' named entity 'IgG' covid:arg/cbfcc8ef7d0b19fda8e3d2001b34744c303af83b named entity 'patients' named entity 'cohort study' named entity 'viral load' named entity 'viral RNA' named entity 'spike protein' named entity 'viral load' named entity 'Serological' named entity 'viral RNA' named entity 'Wenzhou' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'preprint' named entity 'cough' named entity 'infection' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'antibody' named entity 'sputum' named entity 'fever' named entity 'nucleocapsid' named entity 'viral RNA' named entity 'lopinavir' named entity 'false negative results' named entity 'seroconversion' named entity 'antibodies' named entity 'antibodies' named entity 'infection' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'viral load' named entity 'viral persistence' named entity 'long-term' named entity 'sputum' named entity 'diarrhea' named entity 'blood urea nitrogen' named entity 'Wenzhou' named entity 'infection' named entity 'RNA' named entity 'preprint' named entity 'IgM' named entity 'IgM' named entity 'preprint' named entity 'interferon' named entity 'viral infection' named entity 'IgM' named entity 'IgM' named entity 'RBD' named entity 'IgG' named entity 'preprint' named entity 'symptom' named entity 'treat patients' named entity 'medRxiv' named entity 'medRxiv' named entity 'preprint' named entity 'National Health Commission of the People's Republic of China' named entity 'IgM' named entity 'medRxiv' named entity 'peer review' named entity 'virus' named entity 'IgG' named entity 'viral infection' named entity 'antibodies' named entity 'viral load' named entity 'sputum' named entity 'WHO'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software